CONSTELLATION TECHNOLOGIES LIMITED — Capital/Financing Update 2013

Feb 11, 2013

==> picture [99 x 86] intentionally omitted <==

ASX Announcement

Rights Issue Funds To Be Used To Achieve Near Term Commercial Licensing and Partnership Milestones

MELBOURNE, Australia 12 February 2013: Diagnostic and drug development company Agenix Limited (ASX: AGX) today announced all three of its business programs are now the subject of ongoing licensing and partnering discussions with potential commercial partners.

Agenix is commercialising a blood clot diagnostic called ThromboView, a human health point of care diagnostic device platform called DiagnostIQ and a hepatitis B vaccine for China.

The company is providing an update for investors this week. A copy of the presentation is available on the Agenix website (www.agenix.com) and the ASX platform.

Agenix Executive Chairman and Chief Executive Officer Nick Weston told investors, “The current rights issue which closes on 20 February combined with our recent $3 million funding commitment will strengthen our balance sheet and ensure we have the funds as we work towards a number of very important partnering and licensing milestones in 2013.”

He said the board and management intended to take up their full entitlements. The offer will raise $1.2 million if fully subscribed.

Mr Weston told investors Agenix was well positioned with a solid management team, a Phase III ready lead program and positive healthcare industry dynamics driven by payer and user needs to reduce costs and improve levels of care.

For more information please contact:

Nicholas Weston Andrew Geddes Agenix Limited Seed Media Tel: 1300 132 551 T: (02) 9555 4453

Agenix Limited 156 Collins Street, Melbourne, Victoria 3000 Australia Tel: 1300 132 551 ABN 58 009 213 754 www.agenix.com

® ThromboView is a registered trademark of Agen Biomedical Limited, a wholly owned subsidiary of Agenix Limited.

About Agenix

Agenix is focused on the commercialisation of innovative monoclonal antibody blood clot diagnostics, rapid point of need diagnostics and small molecule drugs for the treatment of hepatitis B and other serious diseases. Agenix’s most advanced diagnostic candidate, ThromboView®, a novel radio-labelled monoclonal antibody imaging agent, has completed two Phase 2 clinical trials, and is ideal to diagnose patients indicated for suspected acute pulmonary embolism (PE), with a positive D-dimer blood test or moderate to high pre-test probability of PE, as a replacement diagnostic test for patients with suspected PE where V/Q scans are a first line choice and are unlikely to deliver a diagnostic result, as a confirmatory diagnostic where CT is used as a first-line diagnostic test, the scan result is negative and the clinical probability of disease is high or moderate and as a replacement diagnostic where CTPA is an inappropriate choice based on radiation exposure, renal impairment or contrast allergy.

Agenix’s proprietary diagnostics platform, DiagnostIQ is a patented disposable test device for use with multiple sample types at point-of-care. DiagnostIQ utilises an antibody/antigen printed membrane, a unique pre-filter device and an incubation chamber in a vertical flow through format to create a sensitive and quantitative, rapid, multi-analyte test. The patented technology provides the potential for point-of-need testing that is simple and quick to use, gives rapid and accurate results and is suitable for use with crude samples such as blood, sputum, saliva or plant materials.

Agenix is also developing AGX 1009, a next-generation reverse transcriptase inhibitor (NtRTI) prodrug of tenofovir, for which a CTA is planned to be filed with the Chinese FDA in the second quarter of 2013 and for which the Company plans to partner and advance into Phase 1 in the first half of 2014. Agenix owns all the patent rights to both ThromboView® and AGX 1009. In August 2010, Agenix entered into a collaborative partnership with the Institute of Medicinal Biotechnology of the Chinese Academy of Medical Sciences, part of the Ministry of Health to purchase AGX 1009 and preclinical work is being conducted in Beijing, China by the Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences. Agenix has taken successfully from laboratory to global commercialisation then commercial exit more than 20 products over four technology platforms since listing on the Australian Securities Exchange in 1987.